Loading…
Loading…
Acumen Wealth Advisors LLC increased its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 1,582.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,358 shares of the biopharmaceutical company's stock after buying an additional 5,980 shares during the
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's second quarter 2026 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one.
Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for what could become the first regimen of its kind for the disease.
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacap.
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.
Andra AP fonden decreased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 53.9% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 222,601 shares of the biopharmaceutical company's stock after selling 260,199 shares during the period. Andra AP fonden's holdings in Gilead Sciences were
Dimensional Fund Advisors LP reduced its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 12.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,722,929 shares of the biopharmaceutical company's stock after selling 1,123,384 shares during the
Boston Common Asset Management LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 8.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,243 shares of the biopharmaceutical company's stock after selling 7,238 shares during the quarter.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for GILD and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.